999 results on '"Calvet, X"'
Search Results
2. P1170 Long-term outcomes of newly diagnosed Inflammatory Bowel Disease (IBD) patients: results from the nationwide EpidemIBD study of GETECCU
3. P230 Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry
4. OP37 Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU
5. DOP08 A novel multiomic approach to unravel the mechanisms of action of biologics and tofacitinib in Inflammatory Bowel Disease
6. DOP60 Prevalence of undiagnosed inflammatory Bowel Disease in patients with spondyloarthritis: EISER Study
7. P033 Unrevealing new potential key mechanisms implicated in inflammatory bowel disease by multiomic approach
8. DOP75 Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA
9. P647 Effectiveness of combined treatment with two biologics or advanced molecules in inflammatory bowel disease
10. DOP74 Short and long-term effectiveness and safety of ustekinumab in Ulcerative Colitis in real life: the ULISES study
11. DOP22 Predictive biomarkers of therapeutic response in Inflammatory Bowel Disease: a step towards personalized medicine
12. P895 Analysis of the efficacy of intravenous ustekinumab maintenance treatment in patients with refractory Inflammatory Bowel Disease
13. P268 Decoding the transcriptome of Duchenne muscular dystrophy to the single nuclei level reveals clinical-genetic correlations
14. O02 Unpacking gene expression profile to the single nuclei level in human muscle Pompe samples
15. Patients' perceptions of the impact of ulcerative colitis on social and professional life: results from the UC-LIFE survey of outpatient clinics in Spain
16. Safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease
17. Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry
18. P778 Effectiveness and safety of a second-line rescue therapy for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
19. P410 Long-term persistence and safety of biological drugs in patients with Inflammatory Bowel Disease. Differences between women and men: SEXEII study of ENEIDA
20. P643 Psoriasis induced by anti-TNF therapy in Inflammatory Bowel Disease: analysis of therapeutic management and evolution of both diseases in a nationwide cohort study
21. OP23 Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia
22. P826 Economic impact of inflamatory bowel disease in Catalonia. A population-based analysis
23. P675 Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases
24. P634 Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry
25. Cyclosporine Treatment For Severe Steroid Refractory Immune-Mediated Colitis In A Patient With Ulcerative Colitis
26. P.61 Imaging Mass Cytometry reveals new clues to understand the pathogenesis of Becker muscular dystrophy
27. P.169 Nintedanib improves muscle function and reduces fibrosis in a murine model of alpha-sarcoglycanopthy
28. O.16 Single cell RNA sequencing study of FAPS obtained from muscle samples of DMD patients reveals new pathogenic pathways of the muscle degeneration process
29. P.192 High-throughput screening of antifibrotic and antiadipogenic drugs using human FAP cells
30. Disease severity in familial cases of IBD
31. Phenotype and natural history of elderly onset inflammatory bowel disease: a multicentre, case‐control study
32. OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry
33. Helicobacter pylori inactivation and virulence gene damage using a supported sensitiser for photodynamic therapy
34. P607 Post-operative mortality and predictive factors in a cohort of severe refractory ulcerative colitis patients from the ENEIDA Registry (1989–2013): a multicenter nationwide study
35. P186 Association between anti-TNF serum levels and mucosal healing in inflammatory bowel disease
36. microRNA profiling in duodenal ulcer disease caused by Helicobacter pylori infection in a Western population
37. FEASIBILITY OF UNRESTRICTED DIET VERSUS A 3-DAY LOW-RESIDUE DIET PRE-COLONOSCOPY AND IT IMPACT ONTHE QUALITY OF THE BOWEL PREPARATION
38. USEFULNESS OF THE MODIFIED ROCKALL INDEX TO PREDICT ADVERSE EVENTS IN UPPER GASTROINTESTINAL BLEEDING DUE TO PEPTIC ULCER
39. Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?
40. Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry
41. Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)
42. RhoA/ROCK2 signalling is enhanced by PDGF-AA in fibro-adipogenic progenitor cells: implications for Duchenne muscular dystrophy
43. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU
44. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry
45. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
46. Gastric Intramucosal pH Determination: Limitations of the Technique
47. DOP78 Comparative study of the effectiveness of vedolizumab versus ustekinumab after anti-TNF failure (VERSUS-CD)
48. P289 Evaluation of the safety and effectiveness of direct-acting antiviral drugs in the treatment of hepatitis C in patients with inflammatory bowel disease: National multicenter study (ENEIDA registry). MIC project
49. P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?
50. P654 Clinical outcomes in familial versus sporadic inflammatory bowel disease diagnosed in the era of biological therapies. Prospective data from the ENEIDA registry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.